Bloom CI, Montonen J, Jöns O, Garry EM, Bhatt SP (2022) First maintenance therapy for chronic obstructive pulmonary disease: retrospective analyses of US and UK healthcare databases. Pulm Ther 8(1):57–74. https://doi.org/10.1007/s41030-021-00179-0

Article  PubMed  PubMed Central  Google Scholar 

Cazzola M, Page C, Matera MG (2013) Long-acting muscarinic receptor antagonists for the treatment of respiratory disease. Pulm Pharmacol Ther 26(3):307–317. https://doi.org/10.1016/j.pupt.2012.12.006

Article  CAS  PubMed  Google Scholar 

Stolz D, Cazzola M (2020) Characterising the cardiovascular safety profile of inhaled muscarinic receptor antagonists. In: Martínez-García MA, Pépin J-L, Cazzola M (eds) Cardiovascular complications of respiratory disorders (ERS monograph). European Respiratory Society, Sheffield, pp 238–250

Google Scholar 

Gershon A, Croxford R, Calzavara A, To T, Stanbrook MB, Upshur R, Stukel TA (2013) Cardiovascular safety of inhaled long-acting bronchodilators in individuals with chronic obstructive pulmonary disease. JAMA Intern Med 173(13):1175–1185. https://doi.org/10.1001/jamainternmed.2013.1016

Article  PubMed  Google Scholar 

Zhang C, Zhang M, Wang Y, Xiong H, Huang Q, Shuai T, Liu J (2021) Efficacy and cardiovascular safety of LAMA in patients with COPD: a systematic review and meta-analysis. J Investig Med 69(8):1391–1398. https://doi.org/10.1136/jim-2021-001931

Article  PubMed  PubMed Central  Google Scholar 

Matera MG, Rogliani P, Calzetta L, Cazzola M (2016) Safety considerations with dual bronchodilator therapy in COPD: an update. Drug Saf 39(6):501–508. https://doi.org/10.1007/s40264-016-0402-4

Article  CAS  PubMed  Google Scholar 

Cazzola M, Calzetta L, Rogliani P, Matera MG (2017) Tiotropium formulations and safety: a network meta-analysis. Ther Adv Drug Saf 8(1):17–30. https://doi.org/10.1177/2042098616667304

Article  CAS  PubMed  Google Scholar 

Matera MG, Belardo C, Rinaldi M, Rinaldi B, Cazzola M (2020) Emerging muscarinic receptor antagonists for the treatment of asthma. Expert Opin Emerg Drugs 25(2):123–130. https://doi.org/10.1080/14728214.2020.1758059

Article  CAS  PubMed  Google Scholar 

U.S. Food and Drug Administration (2023) FDA adverse event reporting system (FAERS) public dashboard. https://www.fda.gov/drugs/questions-and-answers-fdas-adverse-event-reporting-system-faers/fda-adverse-event-reporting-system-faers-public-dashboard. Accessed 15 Dec 2023

Silberstein SD, Reshef S, Cohen JM, Gandhi S, Seminerio M, Ramirez Campos V, Kessler Y, Thompson SF, Blumenfeld A (2023) Adverse events reported with therapies targeting the CGRP pathway during the first 6 months post-launch: a retrospective analysis using the FDA adverse events reporting system. Adv Ther 40(2):445–459. https://doi.org/10.1007/s12325-022-02346-4

Article  PubMed  Google Scholar 

Singh S, Loke YK, Enright P, Furberg CD (2013) Pro-arrhythmic and pro-ischaemic effects of inhaled anticholinergic medications. Thorax 68(1):114–116. https://doi.org/10.1136/thoraxjnl-2011-201275

Article  PubMed  Google Scholar 

Verhamme KM, Afonso AS, van Noord C, Haag MD, Koudstaal PJ, Brusselle GG, Sturkenboom MC (2012) Tiotropium Handihaler and the risk of cardio- or cerebrovascular events and mortality in patients with COPD. Pulm Pharmacol Ther 25(1):19–26. https://doi.org/10.1016/j.pupt.2011.10.004

Article  CAS  PubMed  Google Scholar 

Caster O, Aoki Y, Gattepaille LM, Grundmark B (2020) Disproportionality analysis for pharmacovigilance signal detection in small databases or subsets: recommendations for limiting false-positive associations. Drug Saf 43(5):479–487. https://doi.org/10.1007/s40264-020-00911-w

Article  PubMed  PubMed Central  Google Scholar 

Sedgwick P (2013) Case-control studies: measures of risk. BMJ 346:f1185. https://doi.org/10.1136/bmj.f1185

Article  PubMed  Google Scholar 

Rothman KJ, Lanes S, Sacks ST (2004) The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol Drug Saf 13(8):519–523. https://doi.org/10.1002/pds.1001

Article  PubMed  Google Scholar 

Zhai Y, Ye X, Hu F, Xu J, Guo X, Zhuang Y, He J (2019) Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and drug administration adverse events reporting system. J Immunother Cancer 7(1):286. https://doi.org/10.1186/s40425-019-0754-2

Article  PubMed  PubMed Central  Google Scholar 

Ogale SS, Lee TA, Au DH, Boudreau DM, Sullivan SD (2010) Cardiovascular events associated with ipratropium bromide in COPD. Chest 137(1):13–19. https://doi.org/10.1378/chest.08-2367

Article  CAS  PubMed  Google Scholar 

ClinCalc.com (2023) Tiotropium. Drug usage statistics, United States, 2013–2020. https://clincalc.com/DrugStats/Drugs/Tiotropium. Accessed 18 Dec 2023

Tashkin DP, Gross NJ (2018) Inhaled glycopyrrolate for the treatment of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 13:1873–1888. https://doi.org/10.2147/COPD.S162646

Article  CAS  PubMed  PubMed Central  Google Scholar 

Trifilieff A, Ethell BT, Sykes DA, Watson KJ, Collingwood S, Charlton SJ, Kent TC (2015) Comparing the cardiovascular therapeutic indices of glycopyrronium and tiotropium in an integrated rat pharmacokinetic, pharmacodynamic and safety model. Toxicol Appl Pharmacol 287(1):9–16. https://doi.org/10.1016/j.taap.2015.05.012

Article  CAS  PubMed  Google Scholar 

Chapman KR, Beeh KM, Beier J, Bateman ED, D’Urzo A, Nutbrown R, Henley M, Chen H, Overend T, D’Andrea P (2014) A blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 study. BMC Pulm Med 14:4. https://doi.org/10.1186/1471-2466-14-4

Article  PubMed  PubMed Central  Google Scholar 

Kato C, Wang D, Nakamura N, Sasajima T, Yoshisue H (2022) Real-world safety and efficacy of glycopyrronium bromide in Japanese patients with COPD: a 52-week post-marketing surveillance. Open Respir Med J 16:e187430642112240. https://doi.org/10.2174/18743064-v16-e2112240

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gavaldà A, Ramos I, Carcasona C, Calama E, Otal R, Montero JL, Sentellas S, Aparici M, Vilella D, Alberti J, Beleta J, Miralpeix M (2014) The in vitro and in vivo profile of aclidinium bromide in comparison with glycopyrronium bromide. Pulm Pharmacol Ther 28(2):114–121. https://doi.org/10.1016/j.pupt.2014.05.005

Article  CAS  PubMed  Google Scholar 

Rebordosa C, Plana E, Rubino A, Aguado J, Martinez D, Lei A, Daoud S, Saigi-Morgui N, Perez-Gutthann S, Rivero-Ferrer E (2022) Risk assessment of acute myocardial infarction and stroke associated with long-acting muscarinic antagonists, alone or in combination, versus long-acting beta2-agonists. Int J Chron Obstruct Pulmon Dis 17:1715–1733. https://doi.org/10.2147/COPD.S363997

Article  PubMed  PubMed Central  Google Scholar 

Wise RA, Chapman KR, Scirica BM, Bhatt DL, Daoud SZ, Zetterstrand S, Reisner C, Gil EG (2019) Effect of aclidinium bromide on major cardiovascular events and exacerbations in high-risk patients with chronic obstructive pulmonary disease: the ASCENT-COPD randomized clinical trial. JAMA 321(17):1693–1701. https://doi.org/10.1001/jama.2019.4973

Article  CAS  PubMed  PubMed Central  Google Scholar 

Salmon M, Luttmann MA, Foley JJ, Buckley PT, Schmidt DB, Burman M, Webb EF, DeHaas CJ, Kotzer CJ, Barrett VJ, Slack RJ, Sarau HM, Palovich MR, Lainé DI, Hay DW, Rumsey WL (2013) Pharmacological characterization of GSK573719 (umeclidinium): a novel, long-acting, inhaled antagonist of the muscarinic cholinergic receptors for treatment of pulmonary diseases. J Pharmacol Exp Ther 345(2):260–270. https://doi.org/10.1124/jpet.112.202051

Article  CAS  PubMed  Google Scholar 

Babu KS, Morjaria JB (2017) Umeclidinium in chronic obstructive pulmonary disease: latest evidence and place in therapy. Ther Adv Chronic Dis 8(4–5):81–91. https://doi.org/10.1177/2040622317700822

Article  CAS  PubMed  PubMed Central  Google Scholar 

Donohue JF, Niewoehner D, Brooks J, O’Dell D, Church A (2014) Safety and tolerability of once-daily umeclidinium/vilanterol 125/25 mcg and umeclidinium 125 mcg in patients with chronic obstructive pulmonary disease: results from a 52-week, randomized, double-blind, placebo-controlled study. Respir Res 15(1):78. https://doi.org/10.1186/1465-9921-15-78

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cazzola M, Calzetta L, Rinaldi B, Page C, Rosano G, Rogliani P, Matera MG (2017) Management of chronic obstructive pulmonary disease in patients with cardiovascular diseases. Drugs 77(7):721–732. https://doi.org/10.1007/s40265-017-0731-3

Article  CAS  PubMed  Google Scholar 

Posokhova E, Ng D, Opel A, Masuho I, Tinker A, Biesecker LG, Wickman K, Martemyanov KA (2013) Essential role of the m2R-RGS6-IKACh pathway in controlling intrinsic heart rate variability. PLoS ONE 8(10):e76973. https://doi.org/10.1371/journal.pone.0076973

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kulkarni K, Xie X, Fernandez M, de Velasco E, Anderson A, Martemyanov KA, Wickman K, Tolkacheva EG (2018) The influences of the M2R-GIRK4-RGS6 dependent parasympathetic pathway on electrophysiological properties of the mouse heart. PLoS ONE 13(4):e0193798. https://doi.org/10.1371/journal.pone.0193798

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rorabaugh BR, Chakravarti B, Mabe NW, Seeley SL, Bui AD, Yang J, Watts SW, Neubig RR, Fisher RA (2017) Regulator of G protein signaling 6 protects the heart from ischemic injury. J Pharmacol Exp Ther 360(3):409–416. https://doi.org/10.1124/jpet.116.238345

Article  CAS  PubMed  PubMed Central  Google Scholar 

Patanè S (2014) M3 muscarinic acetylcholine receptor in cardiology and oncology. Int J Cardiol 177(2):646–649.